Berberine (C₂₀H₁₈NO₄⁺) is a naturally occurring isoquinoline alkaloid found in medicinal plants such as Coptis chinensis, Phellodendron amurense, and Berberis vulgaris. Its therapeutic use in traditional Chinese medicine dates back approximately 3,000 years to the Shennong Bencao Jing (Divine Farmer’s Classic of Materia Medica). Today, berberine hydrochloride—commonly known as “Huanglian Su”—remains listed in the Pharmacopoeia of the People’s Republic of China as an over-the-counter oral antimicrobial agent for intestinal infections.
Modern pharmacological research has unveiled a remarkably broad therapeutic profile for berberine, encompassing anti-atherosclerotic, hypoglycemic, hypolipidemic, antineoplastic, neuroprotective, and anti-inflammatory activities. Yet this “miracle molecule” has long been shackled by a fundamental pharmacokinetic defect: exceedingly low oral bioavailability.
The root cause lies in its molecular architecture. Berberine comprises three fused aromatic rings that form a flat, hydrophobic shield, effectively repelling water molecules. At 37 °C, the aqueous solubility of berberine hydrochloride is merely 1.02 mg/mL, dropping to 0.50 mg/mL at room temperature. Under the Biopharmaceutics Classification System (BCS), berberine is categorized as a Class IV compound—possessing both low solubility and low permeability.
The bioavailability data are even more sobering. Multiple pharmacokinetic studies have consistently demonstrated an absolute oral bioavailability of less than 1%. In rat models, oral administration of 100 mg/kg yielded an absolute bioavailability of only 0.36%–0.68%; in human trials, oral doses of 400–500 mg produced peak plasma concentrations (Cmax) of merely 0.07–0.4 ng/mL—barely detectable.
This poor bioavailability stems from a triad of mechanisms. First, berberine is a substrate for the efflux transporter P-glycoprotein (P-gp), which actively pumps the compound from intestinal epithelial cells back into the gut lumen. Second, approximately 50% of an oral dose passes through the gastrointestinal tract unabsorbed; the fraction that enters systemic circulation undergoes extensive Phase II metabolism (sulfation and glucuronidation) in the liver. Third, under acidic conditions such as those in gastric fluid, berberine exists in an ionized form prone to self-aggregation, further diminishing its effective solubility and dissolution rate. These pharmacokinetic deficiencies necessitate high daily doses (typically 1.5 g) to achieve therapeutic efficacy, yet such doses provoke gastrointestinal adverse effects including diarrhea, cramping, and nausea—limiting long-term compliance.
To surmount this insoluble “stone,” medicinal chemists turned to a classical yet elegant strategy: salt formation. By pairing the berberine quaternary ammonium cation with alternative counterions, it becomes possible to markedly alter crystal structure, solubility behavior, and membrane permeability. Prior studies have shown that berberine organic salts (e.g., fumarate, succinate) exhibit higher bioavailability than the conventional hydrochloride.
Berberine–ascorbate salt (Berberine Ascorbate Salt) represents a distinguished exemplar of this approach. Its innovation lies in the selection of L-ascorbic acid (vitamin C) as the counterion—a choice underpinned by compelling thermodynamics. The enediol moiety of ascorbic acid possesses a pKa₁ of 4.17, whereas the basic site of berberine exhibits a pKa of approximately 11.5, yielding a ΔpKa of 7.33. According to the “golden rule” of pharmaceutical solid-state chemistry, when ΔpKa exceeds 3, proton transfer proceeds essentially unidirectionally: ascorbic acid donates its proton and becomes the negatively charged ascorbate anion, which electrostatically binds the berberine cation to form a novel ion-pair compound.
This design confers multiple scientific advantages. It eliminates the chloride ion of the traditional salt, removing potential irritancy and hypertonicity concerns. Vitamin C itself contributes antioxidant and immunomodulatory functions, creating a potential pharmacological synergy with berberine. Most critically, the introduction of the ascorbate anion modifies lattice energy, dramatically enhancing aqueous solubility.
At the molecular level, the ascorbate salt opens the “aqueous solubility gate” through three complementary mechanisms. First, the ion-pair effect: the cation–anion pair is highly polarized, allowing water molecules to readily intercalate. Second, hydrogen-bond networking: the multiple hydroxyl groups on the ascorbate anion form extensive hydrogen bonds with water molecules, effectively equipping the “stone” with numerous “water-grabbing handles.” Third, lattice-energy modulation: the salt crystal exhibits moderate lattice energy, permitting facile dissociation in aqueous media.
The experimental data are striking. At 37 °C, the solubility of berberine–ascorbate salt reaches 101.80 mg/mL—approximately 100-fold higher than that of berberine hydrochloride (1.02 mg/mL); at room temperature, the improvement approaches 200-fold. This breakthrough directly addresses the primary barrier limiting absorption under physiologically relevant conditions.
Physically, the ascorbate salt presents as a vivid yellow-to-orange powder, in contrast to the duller yellow of berberine hydrochloride. In aqueous solution, the ascorbate salt forms a clear, transparent solution, whereas berberine hydrochloride yields a turbid suspension—a difference that not only compromises dosing accuracy but also restricts applications in liquid formulations. The markedly enhanced water solubility substantially improves formulation compatibility in functional foods, beverages, and liquid delivery systems.
Pharmacokinetic investigations have validated the in vivo superiority of the ascorbate salt. In a rat model receiving an oral dose of 200 mg/kg, the ascorbate salt group exhibited a Cmax approximately 5–7-fold higher than the hydrochloride group. Onset of absorption was more rapid, with elevated plasma concentrations achieved within 0.25–0.5 hours post-dose. Moreover, plasma drug levels remained appreciably high for 24–36 hours, suggesting a more gradual elimination profile conducive to sustained pharmacological action.
These findings carry profound clinical implications: equivalent plasma exposure can be achieved with a dose reduction exceeding 80%, or, at equivalent doses, pharmacological effects can be substantially potentiated.
The success of the berberine–ascorbate salt is not an isolated case. Researchers continue to explore alternative “keys” for berberine: benzenesulfonate salts demonstrate excellent hygroscopic stability and permeability; phthalate salts improve both moisture resistance and solubility; gallate salts confer additional antibacterial activity, achieving synergistic effects; and sweetener salts (acesulfame, saccharin) address the extreme bitterness of berberine while reducing hygroscopicity and improving tableting performance. Industry data indicate that approximately 50% of marketed drugs are administered as salt forms—a testament to the ubiquity and maturity of this strategy.
Building upon berberine’s established pharmacological activities and the ascorbate salt’s enhanced bioavailability, this novel functional ingredient shows promise across multiple health domains: weight management (via AMPK pathway activation regulating energy metabolism and lipolysis); glycemic optimization (improving insulin sensitivity); gastrointestinal health (the chloride-free formulation potentially reducing mucosal irritation, combined with antibacterial and anti-inflammatory properties); immune health (synergy between berberine’s immunomodulation and vitamin C’s immune support); and anti-inflammatory action (suppression of NF-κB and related inflammatory signaling pathways).
It must be emphasized that currently available data derive primarily from internal testing and animal studies. Clinical human pharmacokinetic data, long-term safety evaluations, and large-scale randomized clinical trials remain to be published and validated. Future research priorities should include human bioequivalence studies, dose optimization, drug–drug interaction profiling, and efficacy confirmation in diverse patient populations (e.g., individuals with diabetes or cardiovascular disease).
From an insoluble “stone” to an exquisite “chemical key,” the story of berberine–ascorbate salt epitomizes the most captivating facet of medicinal chemistry. Through rational salt-form design, a revolutionary improvement in solubility and bioavailability has been achieved without altering berberine’s core pharmacophore—opening new avenues for this ancient herbal constituent in modern functional foods, dietary supplements, and pharmaceutical formulations.
[1] Ai X, et al. Berberine: A Review of its Pharmacokinetics Properties and Therapeutic Potentials in Diverse Vascular Diseases. Front Pharmacol. 2022;13:883459.
[2] Wu D, Wu A. Crystalline berberine ascorbate salt, methods of preparation and applications thereof. US Patent 11345697B1. 2022.
[3] Thomas A, et al. Bioavailability of berberine: challenges and solutions. Istanbul J Pharm. 2021;51(1):141-153.
[4] Chen J, et al. Berberine-loaded solid proliposomes prepared using solution enhanced dispersion by supercritical CO₂: Sustained release and bioavailability enhancement. J Drug Deliv Sci Technol. 2020;56:101528.
[5] El-Menshawe SF, et al. Novel cremochylomicrons for improved oral bioavailability of the antineoplastic phytomedicine berberine chloride. Int J Pharm. 2018;555:131-139.
[6] Cui Y, et al. Development of an Innovative Berberine Food-Grade Formulation with an Ameliorated Absorption. J Food Biochem. 2021;2021:7563889.
[7] Neag MA, et al. Berberine: Botanical Occurrence, Traditional Uses, Extraction Methods, and Relevance in Cardiovascular, Metabolic, Hepatic, and Renal Disorders. Front Pharmacol. 2018;9:557.
[8] Feng X, et al. Berberine in Cardiovascular and Endocrine Diseases: From Phytochemistry to Pharmacology. Evid Based Complement Alternat Med. 2019;2019:1927853.
[9] Habtemariam S. Berberine Pharmacology and the Gut Microbiota: A Hidden Therapeutic Link. Pharmacol Res. 2020;155:104722.
[10] Zhang W, et al. Physicochemical characterization of berberine chloride. AAPS PharmSciTech. 2010;11(3):1356-1364.
[11] Liu L, et al. Improving the hygroscopic stability and permeability of berberine by forming a berberine-benzenesulfonic acid pharmaceutical salt. Cryst Res Technol. 2025;60(7):2300039.
[12] Liu L, et al. Improving hygroscopic stability and solubility of berberine by replacing Cl⁻ with phthalate. J Mol Struct. 2025;1324:139731.
